To the Editor Sheng et al reported that toripalimab significantly improves progression-free survival (PFS) vs dacarbazine and represents a new first-line standard of care for advanced acral melanoma. However, forensic analysis of the subgroup data and effect size reveals this conclusion relies on a methodologically fragile result that fails to translate to the trial’s primary clinical population.
JAMA Oncology published a clinical update in Oncology on 09 Apr 2026.
The item focuses on Challenges in Interpreting MELATORCH Trial Outcomes.
Review the original article for the full source wording and details.